Sutro Biopharma
Market cap $148M 16.6M shares (10-Q, Nov 6, 2026) × $8.92 close Nov 17, 2026
Most recent annual filing: 2026-03-23
- STRO-006 IND filing2026STRO-006 IND filing, 2026, notable
- STRO-227 IND filing2H 2026STRO-227 IND filing, 2H 2026, notable
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (3 active programs)
STRO-227
STRO-006
Technology platforms
XpressCF · Vaxcyte
Cell-free protein synthesis platform enabling rapid production of complex biologics including ADCs, iADCs, bispecific ADCs, and dpADCs for oncology; also licensed to Vaxcyte for infectious disease vaccine development
XpressCF+ · Astellas
Site-specific conjugation platform enabling non-natural amino acid incorporation and precise dual-payload conjugation for homogeneous ADCs, iADCs, bispecific ADCs, and dpADCs in oncology
XpressCF
Proprietary cell-free protein synthesis platform enabling site-specific conjugation and rapid systematic evaluation of protein structure-activity relationships to create optimized homogeneous ADC, bispecific ADC, iADC, and dual-payload ADC product candidates; focus area: oncology
Discontinued (2)
- luveltamab tazevibulin — undisclosed · strategic decision to deprioritize additional investment; development has since been terminated
- STRO-003 — undisclosed · Ipsen decided not to advance STRO-003 program following review of new data and ROR1 landscape; license terminated August 2025
Capital (as filed)
- Cash
- $46.9M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Short-term investments
- $95.3M Sep 30, 2026
- Operating cash flow
- −$22.5M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $142M cash, runway into the first half of 2028 per the update of Nov 12, 2026 — the company's own words as read there, not the filed figure
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (3)
- 2026-11-13 UPDATE: Sutro Biopharma (STRO) - Priced Near Cash 🔒 Paid
- 2026-08-13 UPDATE: Sutro Biopharma (STRO) - The Binary Event Landed 🔒 Paid
- 2026-04-27 Sutro Biopharma (STRO) - Scientific Deep Dive for Lead and Pipeline Products 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (3 calls)
Every verdict Biotech Distilled has published on Sutro Biopharma, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-04-27 Speculative buy speculative Sutro Biopharma (STRO) - Scientific Deep Dive for Lead and Pipeline Products Sutro's cell-free ADC platform offers a differentiated safety profile with a mid-2026 STRO-004 Phase 1 readout as a make-or-break binary catalyst, with the February 2026 financing removing near-term dilution risk.
- 2026-08-13 Buy core UPDATE: Sutro Biopharma (STRO) - The Binary Event Landed STRO-004's Phase 1 data confirmed the safety and PK hypothesis — 12% epistaxis vs. ~70% for Tivdak, 98% DAR8 retention, and CMO execution validated — upgrading from speculative to core buy despite efficacy remaining unquantified.
- 2026-11-13 Buy core UPDATE: Sutro Biopharma (STRO) - Priced Near Cash Despite a 55% decline since the August BUY call, the STRO-004 safety thesis is unchanged, the market cap is near cash value, and the 1H 2027 catalyst remains intact — though an active ATM and admitted CMO friction are real risks.
- Long call · opened Apr 27, 2026 at $33.59 · -73.4% vs XBI +9.2% (Nov 17, 2026)
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Timing, in the company's words (6 quotes from 3 filings)
Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.
-
-
“We expect to provide the next update on STRO-004 development in the first half of 2027.”
matched to STRO-004 · topline data -
“We expect to initiate a Phase 1 clinical trial in connection with STRO-006 in the third quarter of 2026.”
matched to STRO-006 · regulatory submission
-
-
-
“The next STR IV E-01 study update is targeted for the first half of 2027.”
matched to STRO-227 · regulatory submission
-
-
-
“We expect to provide the next update on STRO-004 development in the first half of 2027.”
matched to STRO-004 · readout other -
“We expect to initiate a Phase 1 clinical trial in connection with STRO-006 in the third quarter of 2026.”
matched to STRO-006 · regulatory submission -
“The next STR IV E-01 study update is targeted for the first half of 2027.”
matched to STRO-227 · regulatory submission
-
Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.
Filings & releases (20)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Aug 12, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 12, 2026ReleaseSutro Biopharma Reports Third Quarter 2026 Financial Results and Business Highlightsvia aggregator→ BD updateSummary on the 8-K
- Nov 12, 20268-KCurrent report: results of operations · EX-99.1→ BD updateThree months after STRO-004's debut data, STRO-006 has entered the clinic, Astellas has dosed the first patient in its second iADC program (triggering a $10M milestone), and cash sits at $142.2M — but the stock is down 55% from the August print and the market is clearly not impressed with thesis-intact quarterly updates.
- Nov 12, 202610-QQuarterly report→ BD updateSummary on the 8-K
- Nov 4, 2026ReleaseSutro Biopharma to Participate in Upcoming Investor Conferencesvia aggregator
- Oct 21, 2026ReleaseSutro Biopharma Announces First Patient Dosed in Phase 1 Trial of STRO-006, a Next-Generation ITGB6-Targeting ADC, in Advanced Solid Tumorsvia aggregatorBD extracted 1 program update from this document → STRO pipeline
- Oct 14, 2026Release17th Annual World ADC Conference – Presentations
- Oct 12, 2026ReleaseSutro Biopharma Announces Participation at the 17th Annual World ADC Conferencevia aggregator
- Sep 29, 2026ReleaseSutro Biopharma Appoints Lucas Donigian as Senior Vice President, Business Developmentvia aggregator
- Aug 12, 2026ReleaseSutro Biopharma Reports Second Quarter 2026 Financial Results and Provides Early Update on STRO-004 Phase 1 Studyvia aggregatorBD extracted 1 program update from this document → STRO pipeline
- Aug 12, 20268-KCurrent report: results of operations, Reg FD disclosure · EX-99.1
- Aug 12, 202610-QQuarterly report
- Jun 8, 20268-KCurrent report: shareholder vote
- May 14, 20268-KCurrent report: results of operations · EX-99.1
- May 14, 202610-QQuarterly report
- Apr 22, 2026DEFA14AProxy soliciting material
- Apr 22, 2026DEF 14AProxy statement
- Apr 1, 2026424B3Prospectus (resale / update)
- Mar 23, 2026S-3Shelf registration
- Mar 23, 20268-KCurrent report: agreement terminated, results of operations · EX-99.1
- Mar 23, 202610-KAnnual report
16 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Nov 16, 2026SCHEDULE 13G/A13G amendment
- Nov 9, 2026SCHEDULE 13GPassive >5% holder (13G)
- Aug 14, 2026SCHEDULE 13G/A13G amendment
- Aug 14, 2026SCHEDULE 13G/A13G amendment
- Jul 30, 2026SCHEDULE 13GPassive >5% holder (13G)
- May 15, 2026SCHEDULE 13G/A13G amendment
- May 15, 2026SCHEDULE 13GPassive >5% holder (13G)
- May 14, 2026SCHEDULE 13G/A13G amendment
- May 1, 2026SCHEDULE 13GPassive >5% holder (13G)
- Apr 22, 2026ARSAnnual report to shareholders
- Apr 21, 2026SCHEDULE 13G/A13G amendment
- Apr 21, 2026SCHEDULE 13GPassive >5% holder (13G)
- Apr 1, 2026EFFECTRegistration effective
- Mar 30, 2026CORRESPCORRESP
- Mar 27, 2026UPLOADUPLOAD
- Mar 23, 2026S-8Employee plan registration